Auscann Group Holdings

AusCann is bringing together leading expertise and operations across all aspects of the medical cannabis value chain, beginning with cultivation and production, through to manufacture and distribution of products.

We are an Australian based company and our aim is to produce and provide high quality, economical and clinically validated cannabis medicines to Australian patients.

We have built a strong team of experts and partners with international connections and the right expertise across all aspects of the medicinal cannabis value chain. By leveraging the intellectual property and capabilities of our global partners we are positioned to become a leading producer and provider of cannabis based medications in Australia.

We are initially targeting medications for neuropathic and chronic pain. Medical cannabis has proven to be an effective treatment in the relief from neuropathic and chronic pain and in Australia alone, this is a $9 billion opportunity. Additionally, medical cannabis has shown to be effective in relieving the symptoms of numerous other conditions including treatment resistant epilepsy, chemotherapy induced nausea and spasticity and spasms in multiple sclerosis patients.

Latest Media Releases

AusCann Announces Second Crop Planted in Chile

18/12/2017 08:14:00

AusCann’s 50:50 joint venture, DayaCann, plants its second medicinal cannabis crop in Chile Planting of the crop follows the recent granting of its second cultivation licence by the Chilean…

AusCann Announces Results of Annual General Meeting

24/11/2017 11:38:00

AusCann Group Holdings Ltd (“the Company”) wishes to advise pursuant to Listing Rule 3.13.2 that all resolutions presented at the Annual General Meeting of shareholders held today have bee…

Latest News